细胞行业发展前景诱人却苦于无门进入？德国拉尔思科医疗集团的细胞制备技术输出手把手教你！
 
21世纪是细胞治疗的时代，数以亿计的慢性病患者正等待着细胞治疗，细胞治疗也无可争议地成了朝阳产业，因此细胞行业无论是前景还是“钱景”都非常诱人。也许这令你怦然心动，却苦于无门进入细胞行业，且害怕踩到各种坑。今天我们给你带来的好消息是，德国拉尔思科疫苗集团2021年正式进驻中国上海，愿意分享自己的技术成果，推出了细胞制备技术项目，让你绕开各种坑，而且保姆式的服务，手把手教你，可以让任何零基础的企业或个人搭建起标准的细胞公司。
The development prospect of cell industry is tempting, but it suffers from no way to enter? The cell preparation technology output of Rarsig medical group Germany will teach you hand in hand!
 
The 21st century is the era of cell therapy. Hundreds of millions of patients with chronic diseases are waiting for cell therapy, and cell therapy has undoubtedly become a sunrise industry. Therefore, the cell industry is very attractive in the foreground or "Qian Jing". Perhaps this makes you feel excited, but it is bitter to suffer from no way to enter the cell industry and to be afraid of stepping on various pits. The good news we bring you today is that Rarsig medical group Germany officially entered Shanghai, China in 2021, willing to share its own technological achievements. It has launched a cell preparation technology project, allowing you to bypass various pits. Moreover, nanny-style service and hand-in-hand teaching can enable any zero-based enterprise or individual to build a standard cell company.


 
数量庞大的慢病患者亟需新疗法治疗
早在2016年8月10日，《人民日报》就在当天第4版报道：我国现有确诊慢性病患者近3亿人，其中，一半慢性病负担发生在65岁以下人群。慢性病已成为我国城乡居民死亡的主要原因，据统计，我国城市和农村因慢性病死亡占总死亡人数的比例分别高达86.6%和79.4%。
A large number of patients with chronic diseases are in urgent need of new treatment
 
As early as August 10, 2016, People's Daily reported in the 4th edition of the same day that there are nearly 300 million patients with confirmed chronic diseases in China, half of the burden of which occurs in people under 65 years old. Chronic diseases have become the main cause of death of urban and rural residents in China. According to statistics, the proportion of deaths due to chronic diseases in urban and rural areas in China is as high as 86.6% and 79.4% respectively. 

 2017年1月22日，国务院办公厅印发的《中国防治慢性病中长期规划（2017—2025年）》指出，慢性病主要包括心脑血管疾病、癌症、慢性呼吸系统疾病、糖尿病和口腔疾病，以及内分泌、肾脏、骨骼、神经等疾病。由于病情隐蔽、病程长和治疗整体费用高，慢性病已经成为威胁中国居民健康的最主要因素。
On January 22, 2017, the General Office of the State Council issued the Medium-and Long-Term Plan for Prevention and Treatment of Chronic Diseases in China (2017-2025), pointing out that chronic diseases mainly include cardiovascular and cerebrovascular diseases, cancer, chronic respiratory diseases, diabetes and oral diseases, as well as endocrine, kidney, bone, nerve and other diseases. Due to the hidden illness, long course of disease and high overall cost of treatment, Chronic diseases have become the most important factor threatening the health of Chinese residents. 

 现有的传统疗法对于慢性病治标不治本，通常只能起到缓解症状和延缓疾病进展的作用，很难从根本上治愈慢性病。前瞻产业研究院指出，目前，中国有上亿级别的心血管病患、糖尿病患，以及千万级别的阿尔茨海默病患以及血液肿瘤病患正等待着更积极有效的新疗法治疗。
Existing traditional therapy can only relieve symptoms and delay disease progression, but it is difficult to fundamentally cure chronic diseases. Prospective Industry Research Institute pointed out that at present, there are hundreds of millions of cardiovascular patients, diabetes patients, and tens of millions of Alzheimer's patients and hematological tumor patients in China waiting for more active and effective new treatments.


 
细胞治疗是大势所趋
细胞是人体基本的结构和功能单位。疾病的产生，本质上是“细胞故障”。要从根本上治愈疾病，必须从细胞层面入手加以解决。细胞治疗可以通过干细胞修复损伤细胞，替换衰老或凋亡的细胞，激活休眠干细胞，从而恢复组织器官的功能；可以通过免疫细胞提高患者的免疫力，激活人体自愈力。因此，与传统疗法等外部干预方式相比，细胞治疗可以从根本上祛除疾病，包括慢性病在内的难治性疾病，实现治愈终于有了可能。正如美国前总统奥巴马所说：“干细胞治疗将使绝症或不治之症的词汇消失。” 美国生物学家戴利曾经说过：“如果说20世纪是药物治疗时代，那么21世纪就是细胞治疗的时代。”所言不虚。最近二十年来，以干细胞为代表的细胞治疗研究，带来了重大的科学突破与巨大的产业带动，正引领人类社会迈入细胞治疗时代。
Cell therapy is a general trend
Cells are the basic structural and functional units of human body. The generation of disease is essentially "cell failure". To cure the disease fundamentally, we must solve it from the cellular level. Cell therapy can repair damaged cells, replace aging or apoptotic cells and activate dormant stem cells through stem cells, thus restoring the function of tissues and organs; Immune cells can improve the immunity of patients and activate the self-healing power of human body. Therefore, compared with external interventions such as traditional therapy, cell therapy can fundamentally eliminate diseases, including refractory diseases such as chronic diseases. As former US President Barack Obama said: "Stem cell therapy will make the vocabulary of terminal disease or incurable disease disappear." American biologist Daley once said: "If the 20th century is the era of drug therapy, then the 21st century is the era of cell therapy." What you say is true. In the last two decades, the research on cell therapy represented by stem cells has brought great scientific breakthroughs and great industrial drive, and is leading human society into the era of cell therapy. 
 
2007年、2011年和2012年的诺贝尔生理学或医学奖，都颁发给了在细胞研究领域作出突出贡献的科学家。1999年以来，干细胞与再生医学领域研究成果先后十多次入选世界权威学术期刊《科学》（Science）年度十大科技突破。在国内，多项干细胞研究成果先后荣获国家级大奖。研究表明，干细胞尤其是间充质干细胞能够治疗人体九大系统的100多种疾病，一些难治性疾病有望被干细胞攻克。目前，全球批准上市的细胞药物共有20多款，其中大部分属于干细胞药物。
The Nobel Prize in Physiology or Medicine in 2007, 2011 and 2012 was awarded to scientists who made outstanding contributions in the field of cell research. Since 1999, the research achievements in stem cells and renewable  medicine have been selected as the top ten scientific and technological breakthroughs in the world authoritative academic journal Science for more than ten times. In China, multiple stem cell research results have won the national priz. Studies have shown that stem cells, especially mesenchymal stem cells, can treat more than 100 diseases of nine systems of human body, and some refractory diseases are expected to be overcome by stem cells. At present, there are more than 20 cell drugs approved for marketing in the world, most of which belong to stem cell drugs. 


 
细胞药物被认为是继化学药物、抗体药物之后的第三代药物，但干细胞药物作为一种“活的药物”，有别于其他两种药物，它具有副作用小、安全等优点。诺贝尔生理学或医学奖得主兰迪•谢克曼也曾指出：“从理论上说，应用干细胞技术能治疗各种疾病，且其相较很多传统治疗方法具有无可比拟的优点。”正因为干细胞药物具有副作用小、安全等诸多优点，能够取得其他治疗方法难以达到的治疗效果，许多传统企业纷纷进军干细胞治疗领域，研发干细胞药物。例如，全球制药巨头有礼来、阿斯利康、诺和诺德、赛诺菲、武田制药等，国内大型制药企业有石药集团、天士力医药集团、九芝堂等，甚至与医药无关的传统企业巨头，如，日本富士胶片公司、全球材料巨头戈尔公司、中国家电巨头海尔集团、日本三菱UFJ资本、韩国LG Chem公司等，也在抢滩干细胞治疗。这从侧面反映出，干细胞治疗具有很大的发展机会。
Cell drugs are considered to be a third-generation drug after chemical and antibody drugs, but stem cell drugs, as a "living drug", are different from the other two drugs, and have the advantages of less side effects and safety. Randy Sheckman, winner of the Nobel Prize in Physiology or Medicine, once pointed out: "Theoretically, the application of stem cell technology can treat various diseases, and it has incomparable advantages over many traditional treatments." Due to its advantages, such as less side effects, safety and so on, and can achieve therapeutic effects that are difficult to achieve by other therapeutic methods, many traditional enterprises have entered the field of stem cell therapy and developed stem cell drugs. For example, global pharmaceutical giants Lilly, AstraZeneca, Novo Nordisk, Sanofi, Takeda Pharmaceutical, etc.，and even traditional enterprise giants unrelated to medicine, such as Japan's fujifilm Company, global materials giant Gore Company, Chinese home appliance giant Haier Group, Japan's Mitsubishi UFJ Capital, South Korea's LG Chem Company, etc., are also rushing to the beach for stem cell therapy. This reflects from the side that stem cell therapy has great development opportunities.

 
科技大国已经看到细胞治疗的价值，纷纷将细胞治疗列入国家战略性产业给予大力扶持。在我国，细胞治疗先后列入国家“十三五”和“十四五”计划。近年来，从中央到地方密集出台了各种政策，大力扶持细胞产业的发展。细胞治疗已是大势所趋，是朝阳产业，是创业黄金赛道，是创富标准项目。如果你错过了保健品、房地产、互联网、电商等创富浪潮，就不要再错过细胞治疗的风口！已故著名物理学家霍金说：“未来，干细胞可攻克一切疾病，望来者勇敢开拓新世界！”细胞治疗，一个既能创富，又是治病救人功德无量的项目，我们何乐不去开拓呢？！
Great countries in science and technology have seen the value of cell therapy, and cellular treatment has been promoted to the national strategic industry. In China, cell therapy has been listed in the 13th Five-Year Plan and the 14th Five-Year Plan. In recent years, various policies have been intensively introduced from the central government to the local government to vigorously support the development of the cell industry. Cell therapy isa general trend, a sunrise industry, an entrepreneurial gold track and a standard project for creating wealth. If you miss the wave of wealth creation such as health care products, real estate, Internet and e-commerce, don't miss the outlet of cell therapy! The late famous physicist Hawking said: "In the future, stem cells can overcome all diseases, and hope that newcomers will bravely open up a new world!" Cell therapy, a project that can not only create wealth, but also cure diseases and save people, why don't we develop it? 
 
细胞治疗市场规模巨大
前瞻产业研究院根据近几年来全球干细胞医疗产业的发展变化趋势，以及Technavio发布的研究报告《全球细胞治疗市场2017-2021》分析预测，2024年全球干细胞医疗市场规模将突破2000亿美元，达到2035亿美元。全球市场情报机构Infiniti Research发布的数据则显示，2017-2022年间，全球干细胞治疗市场将以36.52%的复合年增长率增长。
The market of cell therapy is huge
According to the development trend of the global stem cell medical industry in recent years and the research report "Global Cell Therapy Market 2017-2021" released by Technavio, the Prospective Industry Research Institute predicts that the global stem cell medical market will exceed 200 billion US dollars and reach 203.5 billion US dollars in 2024. According to the data released by Infiniti Research, a global market intelligence agency, the global stem cell therapy market will grow at a compound annual growth rate of 36.52% from 2017 to 2022.

 
据前瞻产业研究院发布的《中国干细胞医疗行业发展前景预测与投资战略规划分析报告》统计数据显示，2010年我国干细胞医疗市场规模仅40亿元，到2018年就已经高达657亿元。前瞻产业研究院预测，到2024年中国干细胞医疗产业市场规模将超过1300亿元。有研究也指出，未来随着监管政策的明确以及干细胞药物获批上市，我国干细胞产业的市场潜力巨大，仅干细胞治疗的潜在需求就有可能达到10000亿元。
According to the statistical data of "Analysis Report on Development Prospect Forecast and Investment Strategic Planning of China's Stem Cell Medical Industry" released by Prospective Industry Research Institute, the scale of China's stem cell medical market was only 4 billion yuan in 2010, and it has reached 65.7 billion yuan by 2018. Prospective Industry Research Institute predicts that the market size of China's stem cell medical industry will exceed 130 billion yuan by 2024. Studies have also pointed out that with the clarification of regulatory policies and the approval of stem cell drugs for marketing in the future, the market potential of China's stem cell industry is huge, and the potential demand for stem cell therapy alone may reach 1,000 billion yuan.
 
传统行业转行成本大
正如前述，细胞治疗是大势所趋，朝阳产业，创业黄金赛道，创富标准项目，而且市场规模大。这对于想创业的个人或转型的传统企业来说，这是一个非常难得的机会。于是，很多企业或创业者就急不可耐地闯入细胞行业。殊不知，新入行者来将会踩到各种各样的坑，使得入行成本非常大。
The cost of changing careers in traditional industries is high
As mentioned above, cell therapy is a general trend, a sunrise industry, a entrepreneurial gold track, a standard project for creating wealth, and a large market scale. This is a very rare opportunity for individuals who want to start a business or traditional enterprises in transformation. As a result, many enterprises or entrepreneurs are eager to break into the cell industry. As everyone knows, new entrants will step on a variety of pits, making the cost of entrances.
 
首先，在引进人才、组建团队方面，时间成本较大。招聘新入行的人才，得花时间培训，即使是挖过来是行业经验丰富的人才，也得花时间来和人家磨合。从技术团队和运营团队的组建，到正式投产运营，起码得花半年时间，甚至一年的时间。一年半载，人力成本哗哗地流出去，却没有丝毫收入，谁不会心疼？
First of all, in introducing talents and forming teams, the time cost is relatively high. Recruiting new talents takes time to train, and even if they are experienced talents in the industry, they have to take time to get in touch with others. It takes at least half a year or even one year from the establishment of the technical team and the operation team to the formal production and operation. For a year and a half, the labor cost spouted out, but there was no income at all. Who wouldn't feel distressed? 
 
实验室建设可能会多花冤枉钱
由于是新入行的，缺乏细胞行业的社会关系，需要人托人找人建实验室，这就有可能面临层层的中间人加码抽成的情况，最终可能仅需要1000万元就能建成的实验室，最终却花了2000万元才建成。其中甚至还会出现实验室规划不合理的情况，超出实际应用需要，造成设备等资源的闲置浪费。再次，可能会“重新发明轮子”。市场上明明有成熟的工艺可以引进，但由于新入行不了解情况，埋头哼哧哼哧地自己开发，“重新发明轮子”，这也要耗费巨大的时间成本。
Laboratory construction may cost more money
Since it is a new entrant and lacks social relations in the cell industry, it is necessary to find someone to build a laboratory jointly, which may be faced with the situation that middlemen at different levels overweight and draw. In the end, the laboratory that may only need 10 million yuan can be built, but it cost 20 million yuan to build it. Among them, there will be unreasonable laboratory planning, which exceeds actual application needs,  resulting in idle waste of equipment and other resources. Once again, it may be possible to "reinvent the wheel". There are obviously mature processes that can be introduced in the market, but because new entrants don't know the situation, they bury their heads in developing and "reinventing wheels", which also costs huge time and cost. 
 
德国拉尔思科医疗集团中国分公司-上海塞奥思生物科技有限公司推出了细胞制备技术输出的服务项目，不仅可以让你避开上述这些坑，让你花更少的成本成功入行。而且保姆式的服务，德国专家手把手教你，可以让任何零基础的企业或个人搭建起标准的细胞制备实验室和细胞制备技术，我们保姆式技术输出会助你成功。
Shanghai rarsig Bio-Technology Limited, China Branch of Rarsig medical group Germany , has launched the service project of cell preparation technology export, which can not only help you avoid these pits, but also make you successfully enter the business at less cost. Moreover, nanny service, taught by German experts, can enable any zero-based enterprise or individual to set up a standard cell preparation laboratory and cell preparation technology, and our nanny technology output will help you succeed.

 
上海塞奥思生物科技有限公司是德国拉尔思科医疗集团在中国的唯一分公司，是一家高新技术企业，业务涵盖自体免疫细胞癌症治疗的关键免疫细胞DC-T制备及临床细胞药物研发、再生医学技术研发、细胞质量检测、健康管理等诸多领域。拉尔思科塞奥思先进的细胞治疗技术有着三十年的临床研究与实践经验，特别是增强型自体外周血DC（树突状细胞）技术，纯度高，活化的DC细胞含量均达到1X10的六次方以上，最高可达7000万-9000万活化的DC- T，同时攻克了免疫细胞冻存复苏回收率低的难题，制备周期缩短为7天，有效达到控制成本。拉尔思科新型DC-T技术，德国专家在传统基础上，优化创新培养工艺，从而解决肿瘤易复发、免疫细胞逃逸及治疗实体瘤反应率低的问题。
Shanghai rarsig Bio-Technology Limited. is the only branch of Rarsig medical group Germany in China, and it is a high-tech enterprise. Its business covers the preparation of DC-T, the key immune cell for autoimmune cell cancer treatment, the research and development of clinical cell drugs, the research and development of regenerative medicine technology, the detection of cell quality, health management and many other fields. Rarsig advanced cell therapy technology has 30 years of clinical research and practical experience, especially, the enhanced autologous peripheral blood DC (dendritic cells) technology has high purity, and the content of activated DC cells reaches more than the sixth power of 1X10, up to 70-90 million activated DC-T. At the same time, it overcomes the problem of low recovery rate of cryopreservation and resuscitation of immune cells, shortens the preparation period to 7 days, and effectively achieves cost control. Rarsig new DC-T technology, German experts optimized and innovated the culture technology on the basis of tradition, thus solving the problems of easy recurrence of tumors, escape of immune cells and low response rate in treating solid tumors.

 
具有独立的RARS-DC-T细胞制备知识产权技术
1）Work Instructions 作业指导书
2）Form Sheet 制备数据表
3）Specification Data Sheet 规格数据表
4）Standart Operating Procedure 规范操作程序
5）Quality Assurance Hand Book 质量手册
6）Site Master File 试验中心主档案
Independent intellectual property technology for RARS-DC-T cell preparation
1) Work Instructions
2) Form Sheet  
3) Specification Data Sheet  
4) Standard Operating Procedure
5) Quality Assurance Hand Book  
6) Site Master File

成熟的制备程序
1）7天细胞制备时间，完备的质控体系
2）CD86的活化数量大于1x10的六次方
3）疫苗稳定性高，细胞活性度维持大约24小时
4）通过腹股沟皮下注射，缩短DC进入淋巴结时间，减少DC细胞的损耗
5）血浆抗原，使DC细胞呈递丰富抗原信息，激发更具精准性的免疫反应。
Mature preparation procedure
1) 7 days of cell preparation time, complete quality control system
2) The activated amount of CD86 is greater than the sixth power of 1x10
3) The stability of the vaccine was high, and the cell activity was maintained for about 24 hours
4) Inguinal subcutaneous injection shortens the time of DC entering lymph nodes and reduces the loss of DC cells
5) Plasma antigen makes DC cells present rich antigen information and stimulates more accurate immune response. 

具有独立自主的培养基制备知识产权技术
1）拉尔思科利用自主知识产权培养基开发了冻干浓缩培养基工艺（Blue Box Series BBS），利用该工艺开发高表达 量的细胞培养，使DC培养数量大于10的六次方，降低生产成本。
2）通过该项目的实施，实现了培养基规模生产能力。
Independent intellectual property technology for culture medium preparation
1) Rarsig developed the freeze-dried concentrated culture medium process (Blue Box Series BBS) by using the independent intellectual property culture medium, and developed the cell culture with high expression amount by using this process, so that the DC culture quantity was greater than the sixth power of 10, and the production cost was reduced.
2) Through the implementation of this project, the medium scale production capacity is achieved. 
 
疗效持久性
1）疫苗治疗长效性，细胞质量、数量，以及疫苗的精准性和稳定性带来治疗的长效性，多数患者一年内无需再次治疗。
2）治疗安全性高，通过皮下注射降低安全风险，绿色疗法，无副作用，20年临床应用，无医疗安全事件。
Persistence of curative effect
1) The long-term effect of vaccine treatment, the quality and quantity of cells, and the accuracy and stability of vaccine bring about the long-term effect of treatment, and most patients do not need to be treated again within one year.
2) The treatment has high safety, reduces safety risks through subcutaneous injection, green therapy, no side effects, 20 years of clinical application, and no medical safety incidents.
 
解决自体免疫细胞制备的高价格痛点
细胞治疗从临床到实现产业化还存在诸多痛点，特别是生产流程的统一标准、高昂的制备成本及治疗费用等问题一直困扰着行业发展。 拉尔思科医疗通过优化制备流程，采取统一和创新性发展并进的研发理念，累计资金3000万欧元，通过30年的不断积累，成功实现了降低生产制备成本，为日后工业化生产奠定了坚实的基础。
Solve high price pain points prepared by autologous immune cells
There are still many pain points in cell therapy from clinical practice to industrialization, especially the unified standard of production process, high preparation cost and treatment cost, which have been plaguing the development of the industry. Rarsig medical group Germany has accumulated eur 30 million by optimizing the preparation process and adopting a unified innovation and development philosophy. Through 30 years of continuous accumulation, it has successfully reduced production and preparation costs and laid a solid foundation for future industrial production.


 
全球顶尖专家团队
拉尔思科由全球十家与生物制药相关的公司组成，其覆盖了生物制药及临床的所有生产与治疗环节。
核心技术团队由欧洲知名细胞免疫学与临床医学专家、资深跨学科技术人员与管理专职成员构成。
Top team of experts in the world
Rarsig is composed of ten biopharmaceutical-related companies in the world, covering all manufacturing and therapeutic linkages in biopharmaceutical and clinical practice.
The core technical team consists of well-known European experts in cellular immunology and clinical medicine, senior interdisciplinary technicians and full-time management members. 


 
如今你不用羡慕这些技术，德国拉尔思科集团可以向你直接输出这些技术，服务内容包括请点击： www.rarsig.cn , 我们帮你设计、装修大型、中型、小型等各种类型的细胞药物实验室或传统药物实验室；帮你培养细胞研发生产人才；传授细胞培养制备生产、质量检测等全套细胞技术；教你如何进行市场营销；提供免疫细胞、干细胞的培养基。这完全是一种保姆式的服务，手把手教你，你何愁学不会？所有成熟工艺教给你，免去你花费大量时间重新探索研发。让我们携手共进，同一个梦想合作共赢，共享发展新机遇，创造一个美好的未来。
Now you don't have to envy these technologies. Rarsig medical group Germany can directly export these technologies to you. Service contents include: please click: www.rarsig.cn, and we will help you design and decorate various types of cell drug laboratories or traditional drug laboratories such as large, medium and small ones; Help you train cell R&D and production talents; Teach a complete set of cell technologies such as cell culture, preparation and production, and quality inspection; Teach you how to conduct marketing; Provide culture medium for immune cells and stem cells. This is a kind of nanny-style service. If you are taught by hand, why should you worry about not learning? ! All mature processes are taught to you, providing you with plenty of time to rediscover and develop. Let us work together, win-win cooperation with the same dream, sharing development opportunities, create a better future.